:

Which vaccine is recommended for adults 50 years or greater for reducing the short-term risks of shingles and postherpetic neuralgia?

According to the Centers for Disease Control and Prevention (CDC), about 1 in 3 people in the United States will develop shingles in their lifetime. The recommended vaccine for adults 50 years or greater for reducing the short-term risks of shingles and postherpetic neuralgia is Shingrix, a non-live, recombinant subunit vaccine. This immunization is now the preferred choice over the older Zostavax vaccine, which has been discontinued in the U.S..